劲方医药-B(02595)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02595 劲方医药-B

休市中 10-16 16:08:16

27.860

+0.680

+2.50%

最高29.600	最低27.700	成交量606.32万
今开28.120	昨收27.180	日振幅6.99%
总市值106.70亿	流通市值97.79亿	总股本3.83亿
成交额1.74亿	换手率1.73%	流通股本3.51亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02595","market":"HK","secType":"STK","nameCN":"劲方医药-B","latestPrice":27.86,"timestamp":1792138096007,"preClose":27.18,"halted":0,"volume":6063168,"delay":0,"changeRate":0.025018395879323023,"floatShares":351000000,"shares":383000000,"eps":-6.07,"marketStatus":"休市中","change":0.68,"latestTime":"10-16 16:08:16","open":28.12,"high":29.6,"low":27.7,"amount":174129444,"amplitude":0.069904,"askPrice":27.98,"askSize":5800,"bidPrice":27.86,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-3.946,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792459800000},"marketStatusCode":7,"adr":0,"listingDate":1758211200000,"exchange":"SEHK","adjPreClose":27.18,"openAndCloseTimeList":[[1792114200000,1792123200000],[1792126800000,1792137600000]],"volumeRatio":1.74246,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02595","defaultTab":"news","newsList":[{"id":"2675552395","title":"港股异动 | 劲方医药-B(02595)早盘涨超8% 公司公布KRAS G12D抑制剂多项临床结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2675552395","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675552395?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:59","pubTimestamp":1792115988,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，劲方医药-B早盘涨超8%。截至发稿，涨4.42%，报28.38港元，成交额5032.92万港元。消息面上，10月15日，劲方医药宣布GFH375/VS-7375多项临床研究取得积极进展并公布相关研究的最新数据。目前GFH375在中国已获得中国国家药监局药品审评中心三次纳入突破性治疗品种，针对适应症分别为KRAS G12D突变型胰腺癌、非小细胞肺癌、结直肠癌，并进入单药治疗胰腺癌及NSCLC两项注册性3期研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1508117.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","KCAI","BK1161","VXUS","09939","159938","BK4585","02595","BK1515","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112650930","title":"异动解读｜劲方医药-B盘中上涨8.31%，GFH375/VS-7375多项临床研究进展提振情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1112650930","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112650930?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:35","pubTimestamp":1792114509,"startTime":"0","endTime":"0","summary":"10月16日，劲方医药-B盘中上涨8.31%，报29.18港元，成交额2236.44万港元。消息面上，公司日前披露GFH375/VS-7375多项境内外临床研究取得积极进展，并公布最新数据，带动市场关注度升温。公告显示，GFH375已获得治疗KRAS G12D突变型胰腺癌、非小细胞肺癌及结直肠癌三项突破性疗法认定，并进入胰腺癌及NSCLC两项注册性III期单药研究。公司同时提示，该产品仍处于临床开发阶段，能否最终上市仍存在不确定性。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"劲方医药异动上涨，GFH375临床进展引关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675805371","title":"劲方医药-B盘中涨超8% GFH375/VS-7375多项国内及海外临床研究取得积极进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2675805371","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675805371?lang=zh_cn&edition=full","pubTime":"2026-10-15 09:53","pubTimestamp":1792029180,"startTime":"0","endTime":"0","summary":"模拟交易客户端10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。劲方医药-B盘中涨超8%，截至发稿，股价回落现小涨1.82%，报26.82港元，成交额5595.19万港元。10月15日，劲方医药-B发布公告，GFH375/VS-7375多项国内及海外临床研究取得积极进展并公布相关研究的最新数据。目前GFH375已获得国内治疗KRAS G12D突变型胰腺癌、非小细胞肺癌、结直肠癌的三项突破性疗法认定，并进入单药治疗胰腺癌及NSCLC两项注册性III期研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-10-15/doc-inivhiep7422940.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159938","BK1574","BK1515","09939","BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675379245","title":"港股异动 | 劲方医药-B(02595.HK)涨超4% GFH375/VS-7375多项国内及海外临床研究取得积极进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2675379245","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675379245?lang=zh_cn&edition=full","pubTime":"2026-10-15 09:40","pubTimestamp":1792028411,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1574","02595","09939","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115784796","title":"劲方医药-B（02595）披露GFH375/VS-7375最新临床进展　多项III期试验加速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1115784796","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115784796?lang=zh_cn&edition=full","pubTime":"2026-10-15 08:16","pubTimestamp":1792023372,"startTime":"0","endTime":"0","summary":"2026年10月15日，劲方医药科技（上海）股份有限公司发布自愿公告，通报口服KRAS G12D抑制剂GFH375/VS-7375在境内外多项临床研究的最新进展与关键数据。截至目前，GFH375已获中国境内针对KRAS G12D突变型胰腺癌、非小细胞肺癌及结直肠癌的三项突破性疗法认定，并已进入针对胰腺癌及NSCLC的两项注册性III期单药治疗研究。公司在公告中提醒，GFH375/VS-7375仍处于临床开发阶段，无法保证最终成功上市。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675637324","title":"劲方医药-B(02595)：GFH375/VS-7375多项国内及海外临床研究取得积极进展，在多种 RAS 突变实体瘤中显示优秀疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=2675637324","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675637324?lang=zh_cn&edition=full","pubTime":"2026-10-15 08:02","pubTimestamp":1792022533,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B 发布公告，GFH375/VS-7375 多项国内及海外临床研究取得积极进展并公布相关研究的最新数据。目前 GFH375 已获得国内治疗 KRAS G12D 突变型胰腺癌、非小细胞肺癌 、结直肠癌的三项突破性疗法认定，并进入单药治疗胰腺癌及 NSCLC 两项注册性 III 期研究 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1507414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1574","BK1515","09939","BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182744706","title":"劲方医药-B10月13日回购3.80万股，耗资约102.52万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1182744706","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182744706?lang=zh_cn&edition=full","pubTime":"2026-10-13 19:02","pubTimestamp":1791889347,"startTime":"0","endTime":"0","summary":"劲方医药科技（上海）股份有限公司于2026年10月13日公告，公司当日于香港联交所场内回购股份3.80万股，占回购前公司已发行股本约0.011%。本次回购的每股价格介于每股26.92港元至27港元之间，总耗资约102.52万港元。公司此前于2026年5月11日通过回购授权，可回购的股份总数为37,036,663股，截至本次回购后，公司已合计回购1,161,000股，占回购授权通过当日已发行股份约0.313%。公司确认已遵守香港联合交易所有限公司证券上市规则及相关法律规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"劲方医药-B10月13日回购3.80万股，耗资约102.52万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675355707","title":"劲方医药-B(02595.HK)10月13日耗资约102.52万港元回购3.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2675355707","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675355707?lang=zh_cn&edition=full","pubTime":"2026-10-13 19:02","pubTimestamp":1791889326,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02595","BK1515","BK1574","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152736320","title":"异动解读｜劲方医药-B盘中下跌5.07%，股东减持与回购力度不足持续施压","url":"https://stock-news.laohu8.com/highlight/detail?id=1152736320","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152736320?lang=zh_cn&edition=full","pubTime":"2026-10-13 09:39","pubTimestamp":1791855541,"startTime":"0","endTime":"0","summary":"10月13日，劲方医药-B盘中下跌5.07%，报26.04港元，成交额624.42万港元。消息面上，公司近期遭遇重要股东减持，而回购力度相对有限，未能有效对冲抛压。根据此前披露，9月24日Ourea Biotech HK Limited减持劲方医药-B 600万股，每股作价27.3港元，总金额约1.638亿港元，减持后持股比例降至4.64%。与此同时，公司虽自9月以来持续实施H股回购，10月8日亦回购13.5万股、耗资约383.07万港元，但累计回购规模尚难以完全消化减持带来的卖压，市场情绪持续偏弱。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"劲方医药盘中下跌，股东减持压力持续","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128685424","title":"异动解读｜劲方医药-B盘中下跌5.11%，股东减持压力与回购力度不足持续施压","url":"https://stock-news.laohu8.com/highlight/detail?id=1128685424","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128685424?lang=zh_cn&edition=full","pubTime":"2026-10-09 10:13","pubTimestamp":1791512015,"startTime":"0","endTime":"0","summary":"10月9日，劲方医药-B盘中下跌5.11%，报26.72港元，成交额1796.36万港元。消息面上，近期重要股东减持动作与相对有限的公司回购规模形成鲜明对比，持续对股价构成压力。与此同时，公司虽自9月以来持续实施H股回购，10月8日亦回购13.5万股、耗资约383.07万港元，但累计回购规模相对有限，未能有效对冲减持带来的抛压。公司近期亦面临董事辞任及股价持续波动等多重因素交织，市场情绪偏弱。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"劲方医药盘中下跌，股东减持压力施压","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127746569","title":"劲方医药-B：10月8日回购13.5万股，耗资约383.07万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1127746569","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127746569?lang=zh_cn&edition=full","pubTime":"2026-10-08 19:46","pubTimestamp":1791459989,"startTime":"0","endTime":"0","summary":"劲方医药科技(上海)股份有限公司于2026年10月8日发布公告，披露公司于当日在香港联交所场内回购普通股合计13.5万股，约占该次回购前已发行股本的0.039%。本次回购价格区间介于每股27.80港元至28.74港元，合计支付约383.07万港元。根据2026年5月11日通过的回购授权，公司可回购股份总数为37,036,663股，截至目前已在香港联交所或其他证券交易所合计回购1,123,000股，占授权总数的0.303%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"劲方医药-B：10月8日回购13.5万股，耗资约383.07万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673074377","title":"劲方医药-B(02595)10月8日斥资383.07万港元回购13.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2673074377","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673074377?lang=zh_cn&edition=full","pubTime":"2026-10-08 19:43","pubTimestamp":1791459805,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，于2026年10月8日斥资383.07万港元回购13.5万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1504837.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1161","BK1574","159938","09939","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673074306","title":"劲方医药-B(02595.HK)10月8日斥资383.07万港元回购13.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2673074306","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673074306?lang=zh_cn&edition=full","pubTime":"2026-10-08 19:43","pubTimestamp":1791459805,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1574","02595","09939","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183465796","title":"异动解读｜劲方医药-B盘中下跌6.61%，重要股东减持叠加回购规模有限引发抛压","url":"https://stock-news.laohu8.com/highlight/detail?id=1183465796","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183465796?lang=zh_cn&edition=full","pubTime":"2026-10-08 09:39","pubTimestamp":1791423565,"startTime":"0","endTime":"0","summary":"10月7日，劲方医药-B盘中下跌6.61%，报31.5港元，成交额146.73万港元。消息面上，公司近期面临重要股东减持与回购护盘力度不足的双重压力。9月24日，重要股东Ourea Biotech HK Limited在场内以每股均价27.3港元减持600万股，涉资约1.64亿港元，好仓比例由6.34%降至4.64%，低于5%的披露门槛。同期，公司虽在9月持续回购H股，累计回购约98.8万股并持作库存股，但回购规模相对有限，未能有效对冲减持带来的抛压，引发市场对公司短期估值信心的担忧。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"劲方医药遭重要股东减持，抛压引发股价下挫","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159558569","title":"异动解读｜劲方医药-B盘中下跌5.12%，重要股东减持叠加回购规模有限引发抛压","url":"https://stock-news.laohu8.com/highlight/detail?id=1159558569","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159558569?lang=zh_cn&edition=full","pubTime":"2026-10-07 09:41","pubTimestamp":1791337300,"startTime":"0","endTime":"0","summary":"10月7日，劲方医药-B盘中下跌5.12%，报31.5港元，成交额146.73万港元。近期公司面临多重消息面压力。9月24日，重要股东Ourea Biotech HK Limited在场内以每股均价27.3港元减持600万股，涉资约1.64亿港元，好仓比例由6.34%降至4.64%。此次减持后，相关方持股已低于5%的披露门槛，市场解读为机构投资者对公司短期估值态度趋于谨慎。与此同时，公司在9月持续进行H股回购，累计回购约98.8万股并持作库存股，但回购规模相对有限，未能有效对冲减持带来的抛压。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"劲方医药盘中下跌，股东减持引发抛压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170349002","title":"劲方医药-B发布9月股份变动月报，回购并持有988,000股H股","url":"https://stock-news.laohu8.com/highlight/detail?id=1170349002","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170349002?lang=zh_cn&edition=full","pubTime":"2026-10-05 16:38","pubTimestamp":1791189497,"startTime":"0","endTime":"0","summary":"劲方医药科技（上海）股份有限公司于2026年10月5日披露截至2026年9月30日止当月的股份变动月报。报告期内，公司已发行股本总额维持在351,629,020股H股与32,337,610股未上市普通股，法定（注册）股本总额人民币38,396,663元保持不变。根据公告，本月公司回购H股合计988,000股，并将上述购回股份持作库存股。本次报告由公司联席公司秘书张巍签署。根据公告披露，截至9月底，公司各类股本结构基本维持稳定，无其他增发或注销安排。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104594468","title":"异动解读｜劲方医药-B盘中下跌5.09%，前期急涨后大股东减持及生物科技板块普跌承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1104594468","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104594468?lang=zh_cn&edition=full","pubTime":"2026-10-02 10:25","pubTimestamp":1790907957,"startTime":"0","endTime":"0","summary":"10月2日，劲方医药-B盘中下跌5.09%，报31.32港元，成交额671.7万港元。公司此前连续两个交易日大幅反弹，10月1日单日涨幅达11.56%，短期累计涨幅较大，存在获利回吐压力。消息面上，Ourea Biotech HK Limited于9月24日场内减持公司600万股，每股作价27.3港元，涉资约1.64亿港元，持股比例由6.34%降至4.64%，大股东减持形成潜在抛压。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"劲方医药急涨后回落，遭大股东减持","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169622221","title":"异动解读｜劲方医药-B盘中上涨5.27%，GFH375突破性疗法认定叠加回购持续提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1169622221","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169622221?lang=zh_cn&edition=full","pubTime":"2026-09-30 09:41","pubTimestamp":1790732476,"startTime":"0","endTime":"0","summary":"9月30日，劲方医药-B盘中上涨5.27%，报31.14港元，成交额1316.45万港元，延续前一交易日反弹走势。消息面上，公司在研口服KRAS G12D抑制剂GFH375联合西妥昔单抗治疗结直肠癌适应症被CDE拟纳入突破性治疗品种，若通过公示期将为GFH375第三次获得突破性疗法认定。此外，公司年内已累计回购10次，合计回购98.8万股、耗资约2557.98万港元。公司将于10月15日公布GFH375联合西妥昔单抗治疗KRAS G12D突变实体瘤的初步研究数据，临床催化剂密集。交银国际及中信建投均维持买入评级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"劲方医药异动拉升，GFH375获突破性疗法","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671747216","title":"Ourea Biotech HK Limited减持劲方医药-B(02595)600万股 每股作价27.3港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671747216","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671747216?lang=zh_cn&edition=full","pubTime":"2026-09-29 19:15","pubTimestamp":1790680502,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，9月24日，Ourea Biotech HK Limited减持劲方医药-B600万股，每股作价27.3港元，总金额为1.638亿港元。减持后最新持股数目约为1630.69万股，最新持股比例为4.64%。本交易涉及其他关联方：HL GP II Company Limited、HL Partners II L.P.补充资料：Ourea Biotech由HL Partners II L.P.控制，而HL Partners II L.P.是一家根据开曼群岛法律成立的有限合伙企业，最终由其普通合伙人HL GP II Company Limited管理。因此，根据证券及期货条例，HL Partners II L.P.及HL GP II Company Limited各自被视为于Ourea Biotech所持股份中拥有权益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502210.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","EWH","BK1574","BK1515","BK4581","09939","XBI","BK1161","BK4585","BK4588","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153964670","title":"劲方医药-B：HL Partners II L.P.减持，好仓比例降至4.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=1153964670","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153964670?lang=zh_cn&edition=full","pubTime":"2026-09-29 17:41","pubTimestamp":1790674878,"startTime":"0","endTime":"0","summary":"HL Partners II L.P.于2026年9月24日在联交所场内以每股均价27.3港元卖出劲方医药-B（02595）股份600.00万股，涉资约1.64亿港元，属场内主动交易，即在二级市场直接买卖股份。HL Partners II L.P.此次减持前持有劲方医药-B好仓2230.69万股，占比6.34%；减持后持股量为1630.69万股，好仓比例降至4.64%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.genfleet.com","stockEarnings":[{"period":"1week","weight":-0.0259},{"period":"1month","weight":0.1279},{"period":"3month","weight":-0.2196},{"period":"6month","weight":-0.3882},{"period":"1year","weight":-0.1071},{"period":"ytd","weight":0.1716}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":-0.0213},{"period":"3month","weight":-0.0153},{"period":"6month","weight":-0.0754},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":-0.0563}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"劲方医药科技（上海）有限公司是一家专注于创新药物研发的中国公司。该公司为肿瘤、自身免疫性疾病和炎症性疾病提供有效的新型治疗方案。该公司的研发平台涵盖靶点发现、分子发现与评估、转化科学和临床开发，以及制剂研究、工艺开发和质量分析等关键化学生产和控制环节。该公司主要致力于新分子类型和新药物模式的开发，分子工艺路线和质量标准的研究，以及差异化临床开发策略和路径的探索。该公司主要在中国国内和海外市场开展业务。","exchange":"SEHK","name":"劲方医药-B","nameEN":"GENFLEET-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"劲方医药-B(02595)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供劲方医药-B(02595)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"劲方医药-B,02595,劲方医药-B股票,劲方医药-B股票老虎,劲方医药-B股票老虎国际,劲方医药-B行情,劲方医药-B股票行情,劲方医药-B股价,劲方医药-B股市,劲方医药-B股票价格,劲方医药-B股票交易,劲方医药-B股票购买,劲方医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"劲方医药-B(02595)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供劲方医药-B(02595)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}